Form 4: Aurinia CFO's Stock Transactions Revealed

Aurinia Pharmaceuticals CFO Joseph M. Miller reported the acquisition of performance-based shares and subsequent tax-related dispositions, adjusting his beneficial ownership.

Summary

• Joseph M. Miller, Chief Financial Officer of Aurinia Pharmaceuticals Inc. (AUPH), reported changes in his beneficial ownership of the company's common stock.
• On January 2, 2026, Miller acquired 49,038 common shares as part of a performance award, with no stated acquisition price.
• These performance award shares are scheduled to vest in two equal annual installments on December 31, 2025, and December 31, 2026.
• Concurrently, on January 2, 2026, 40,161 common shares were disposed of at a price of $15.95 per share to satisfy tax withholding obligations related to the vesting of performance awards.
• Following these transactions, Miller's direct beneficial ownership stands at 589,127 common shares.
• This total includes 1,721 common shares acquired on May 30, 2025, and 1,168 common shares acquired on November 28, 2025, through the Issuer's 2021 Employee Share Purchase Plan.

Sentiment

Score: 5

Explanation: The filing is largely factual, reporting routine insider transactions. The acquisition of performance shares is positive, while the disposition for tax withholding is a neutral, common event.

Positives

• CFO Joseph M. Miller earned 49,038 common shares through a performance award, indicating achievement of company performance metrics.
• The acquisition of shares through the Employee Share Purchase Plan (ESPP) on two separate occasions (1,721 shares on May 30, 2025, and 1,168 shares on November 28, 2025) demonstrates continued insider investment and alignment with shareholder interests.

Negatives

• 40,161 common shares were disposed of at $15.95 per share to cover tax withholding obligations, representing a reduction in direct beneficial ownership.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook, focusing solely on past and scheduled insider transactions.

Industry Context

This Form 4 filing details routine insider transactions for a pharmaceutical company's Chief Financial Officer, which is a standard disclosure requirement and does not inherently reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The CFO's continued ownership and acquisition of shares through performance awards and ESPP may signal confidence in the company's future. The tax-related disposition is a common event and generally not a negative signal.
• Employees: The existence of performance awards and an Employee Share Purchase Plan (ESPP) indicates programs designed to align employee interests with company performance and provide opportunities for equity ownership.

Next Steps

• The remaining portion of the performance award shares will vest on December 31, 2026.

Key Dates

Keywords

AUPH, Aurinia Pharmaceuticals, Form 4, insider trading, stock transactions, CFO, Joseph M. Miller, performance awards, share ownership, ESPP